|
Surveyed U.S. Neurologists Would Prescribe Biogen Idec’s Tecfidera to 20 …
PR Newswire (press release) Clinical data and the opinions of thought leaders interviewed by Decision Resources indicate that other emerging agents—Lemtrada, ocrelizumab and AbbVie/Biogen Idec’s daclizumab—have advantages in reducing ARR over Teva’s Copaxone, the … |
|
This Week in Biotech
Motley Fool The end of the week also brought good news for Biogen Idec (NASDAQ: BIIB ) investors — as if you haven’t been riding high already from the approval of Tecfidera — when the company announced positive midstage results for Daclizumab for the treatment … |
|
Biogen Hits Primary Endpoints in MS Study
Motley Fool Biotech company Biogen Idec’s (NASDAQ: BIIB ) developmental multiple sclerosis drug daclizumab succeeded in the SELECT phase 2b trial evaluating its safety and effectiveness in treating patients with relapse-remitting MS. The trial results, originally … Biogen Idec Inc. (NASDAQ:BIIB) Jumps over 34% in 3 Months As Positive MS …Galaxy Stocks |
Reducing Relapse with New MS MedicationdailyRxPatients were assigned to take daclizumab or placebo (fake medication) every four weeks for 52 weeks. A total of 208 patients were assigned to 150 mg doses of daclizumab, 209 were assigned to 300 mg doses o…
Galaxy StocksBiogen Idec Inc. (NASDAQ:BIIB) Jumps over 34% in 3 Months As Positive MS …Galaxy StocksShares of Biogen Idec Inc. (NASDAQ:BIIB) got a raise in the opening minutes of trading on Thursday following the firm declared results from its multip…
 Hannover Zeitung |
Daclizumab HYP halbiert die Wahrscheinlichkeit von MS-Schüben
MyHandicap Auf der Suche nach neuen Medikamenten gegen die schubförmige Multiple Sklerose (MS) haben Forscher unter Studienleitung der Neurologie des RUB-Klinikums St. Josef Hospital (Prof. Dr. Ralf Gold) einen erfolgversprechenden Kandidaten getestet: … Multicenterstudie: Neues Medikament könnte bei Multiple Sklerose die …DMSG Multiple Sklerose Nachrichten Erfolg versprechend: Neues Medikament gegen Multiple Sklerose – idwInformationsdienst Wissenschaft (Pressemitteilung) Multiple Sklerose: Bochumer Wissenschaftler erforschen neue …Westfalen heute |
Hannover Zeitung |
Multiple Sklerose: Daclizumab HYP halbiert Schubfrequenz
Deutsches Ärzteblatt Bochum – Der monoklonale Antikörper Daclizumab HYP, eine Variante des 1999 zur Prophylaxe akuter Abstoßungsreaktionen nach Nierentransplantation eingeführten Immunsuppressivums Daclizumab, hat in einer Phase-II-Studie vielversprechende … Multiple Sklerose: Daclizumab HYP halbiert die Wahrscheinlichkeit von SchübenInformationsdienst Wissenschaft (Pressemitteilung) Vielversprechender neuer Wirkstoff gegen Multiple SklerosederStandard.at |
|
Lancet Publishes SELECT Study of Biogen’s Daclizumab HYP, Biogen Says …
Benzinga Today Biogen Idec (NASDAQ: BIIB) announced that results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial have been published as an online article in The Lancet. SELECT was a Phase 2b study designed to determine the efficacy … Market opening: Biogen Idec up after positive MS drug studyMarketWatch (blog) |
The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of …Financial PostToday Biogen Idec (NASDAQ: BIIB) announced that results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial have been published as an online article…
The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of …MarketWatch (press release)Today Biogen Idec (NASDAQ:BIIB) announced that results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial have been published as an on…